International urology and nephrology · 2026
Therapeutic efficacy and predictive factors for a successful outcome after platelet-rich plasma injections in men with post-prostatectomy urinary incontinence.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Chia-Cheng, Jiang Yuan-Hong, Kuo Hann-Chorng
Аннотация
PURPOSE: Post-prostatectomy incontinence (PPI) is a well-recognized complication of transurethral or radical prostatectomy. Platelet-rich plasma (PRP) has been used in regenerative medicine. This study aimed to evaluate the therapeutic efficacy of repeated PRP injections into the urethral sphincter for PPI.
METHODS: Totally 71 patients with PPI refractory to conservative treatments. Each patient received four monthly PRP injections into the urethral sphincter. The primary endpoint was the Global Response Assessment (GRA) score for urinary incontinence improvement. Secondary endpoints included changes in the visual analog scale (VAS) for urinary incontinence, the Urogenital Distress Inventory (UDI-6), the Incontinence Impact Questionnaire (IIQ-7), daily pad usage, and urodynamic parameters three months after the fourth PRP injection.
RESULTS: The mean age was 71.0 ± 7.2 years, with a mean PPI duration of 35.5 ± 36.8 months. After PRP injections, the mean GRA score was 1.30 ± 1.23. A GRA score of 2 or 3 was reported in 29 (40.8%) patients, and a GRA score of = 1 was reported in 27 (38.0%), and 15 (21.1%) showed no improvement or reported worsening. Significant improvements were observed in the VAS score, UDI-6 score, and abdominal leak point pressure (ALPP). The increase in ALPP was significantly greater in the successful group than in the failed group (49.3 ± 78.3 vs. 4.9 ± 52.4 cmH2O, p = 0.028). Baseline cystometric bladder capacity (CBC) was identified as a significant predictor of a successful outcome (p = 0.047).
CONCLUSIONS: Repeated urethral sphincter PRP injections can reduce the severity of PPI and increase ALPP in 40.8% patients with PPI. The results of this study support PRP as an exceptional therapy with low success but few complications.
METHODS: Totally 71 patients with PPI refractory to conservative treatments. Each patient received four monthly PRP injections into the urethral sphincter. The primary endpoint was the Global Response Assessment (GRA) score for urinary incontinence improvement. Secondary endpoints included changes in the visual analog scale (VAS) for urinary incontinence, the Urogenital Distress Inventory (UDI-6), the Incontinence Impact Questionnaire (IIQ-7), daily pad usage, and urodynamic parameters three months after the fourth PRP injection.
RESULTS: The mean age was 71.0 ± 7.2 years, with a mean PPI duration of 35.5 ± 36.8 months. After PRP injections, the mean GRA score was 1.30 ± 1.23. A GRA score of 2 or 3 was reported in 29 (40.8%) patients, and a GRA score of = 1 was reported in 27 (38.0%), and 15 (21.1%) showed no improvement or reported worsening. Significant improvements were observed in the VAS score, UDI-6 score, and abdominal leak point pressure (ALPP). The increase in ALPP was significantly greater in the successful group than in the failed group (49.3 ± 78.3 vs. 4.9 ± 52.4 cmH2O, p = 0.028). Baseline cystometric bladder capacity (CBC) was identified as a significant predictor of a successful outcome (p = 0.047).
CONCLUSIONS: Repeated urethral sphincter PRP injections can reduce the severity of PPI and increase ALPP in 40.8% patients with PPI. The results of this study support PRP as an exceptional therapy with low success but few complications.